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ABSTRACT Poor penetration through the outer membrane (OM) of Gram-negative
bacteria is a major barrier of antibiotic development. While -lactam antibiotics are com-
monly used against Klebsiella pneumoniae and Enterobacter cloacae, there are limited
data on OM permeability especially in K. pneumoniae. Here, we developed a novel cas-
sette assay, which can simultaneously quantify the OM permeability to five -lactams in
carbapenem-resistant K. pneumoniae and E. cloacae. Both clinical isolates harbored a
blaKPC-2 and several other -lactamases. The OM permeability of each antibiotic was
studied separately (“discrete assay”) and simultaneously (“cassette assay”) by determining
the degradation of extracellular -lactam concentrations via multiplex liquid chromato-
graphy-tandem mass spectrometry analyses. Our K. pneumoniae isolate was polymyxin
resistant, whereas the E. cloacae was polymyxin susceptible. Imipenem penetrated the
OM at least 7-fold faster than meropenem for both isolates. Imipenem penetrated E. clo-
acae at least 258-fold faster and K. pneumoniae 150-fold faster compared to aztreonam,
cefepime, and ceftazidime. For our -lactams, OM permeability was substantially higher
in the E. cloacae compared to the K. pneumoniae isolate (except for aztreonam). This cor-
related with a higher OmpC porin production in E. cloacae, as determined by proteom-
ics. The cassette and discrete assays showed comparable results, suggesting limited or
no competition during influx through OM porins. This cassette assay allowed us, for
the first time, to efficiently quantify the OM permeability of multiple -lactams in
carbapenem-resistant K. pneumoniae and E. cloacae. Characterizing the OM permeability
presents a critical contribution to combating the antimicrobial resistance crisis and en-
ables us to rationally optimize the use of -lactam antibiotics.
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IMPORTANCE Antimicrobial resistance is causing a global human health crisis and is
affecting all antibiotic classes. While -lactams have been commonly used against
susceptible isolates of Klebsiella pneumoniae and Enterobacter cloacae, carbapenem-
resistant isolates are spreading worldwide and pose substantial clinical challenges.
Rapid penetration of -lactams leads to high drug concentrations at their periplas-
mic target sites, allowing -lactams to more completely inactivate their target recep-
tors. Despite this, there are limited tangible data on the permeability of -lactams
through the outer membranes of many Gram-negative pathogens. This study pres-
ents a novel, cassette assay, which can simultaneously characterize the permeability
of five -lactams in multidrug-resistant clinical isolates. We show that carbapenems,
and especially imipenem, penetrate the outer membrane of K. pneumoniae and E.
cloacae substantially faster than noncarbapenem -lactams. The ability to efficiently
characterize the outer membrane permeability is critical to optimize the use of
-lactams and combat carbapenem-resistant isolates.
KEYWORDS Enterobacter cloacae, Klebsiella pneumoniae, LC-MS/MS, beta-lactams,
carbapenem resistance, carbapenems, cassette assay, cephalosporins, monobactams,
outer membrane, permeability, polymyxin resistance
Multidrug-resistant (MDR) Gram-negative bacteria are causing an urgent, globalthreat to human health (1). The outer membrane (OM) of Gram-negative species
presents a formidable penetration barrier for antibiotics (2–4). Therefore, characterizing
the rate of OM penetration is important to identify antibiotics that can reach high and
effective target site concentrations (5). -Lactams have been used for decades against
susceptible isolates of Klebsiella pneumoniae and Enterobacter cloacae complex; how-
ever, their clinical utility has been compromised by the global rise of carbapenem-
resistant (CR) isolates. More recently, many of these CR isolates have additionally gained
resistance to polymyxins (6). To bind their bacterial target receptors in the periplasm,
-lactams have to penetrate the OM. However, there is limited tractable data on the
rate of OM permeability for -lactams in K. pneumoniae and many other Gram-negative
species. More permeability data are available for Escherichia coli (7) and, to a lesser
degree, Pseudomonas aeruginosa (8) and E. cloacae complex (9). For the latter patho-
gen, permeability data on carbapenems are lacking though.
-Lactams are hydrophilic molecules, which penetrate the OM via one or multiple
different porin channels. Once in the periplasm, -lactams are subject to -lactamase-
mediated hydrolysis, the effect of efflux pump(s) (10), and covalent binding to their
penicillin-binding protein (PBP) target receptors (11). The relative rates of these pro-
cesses determine the target site concentration of -lactams and ultimately the extent
of inactivation of the PBPs (i.e., transpeptidases) in the periplasm. Simultaneous com-
binations of two -lactams (i.e., double -lactam therapy) have been evaluated with
promising results in large clinical trials in the 1970s and 1980s (12). For such combi-
nations, it is important to assess that both of the -lactams can efficiently penetrate
through OM porin(s) at the same time. To our knowledge, there are currently no data
on a potential interaction of -lactams during influx. Moreover, combination therapies
using a -lactam with a polymyxin or an aminoglycoside have been used to combat
MDR isolates. The latter two antibiotics offer the possibility to permeabilize the OM
toward the -lactam as a mechanism of synergy (13–16). Overall, the ability to char-
acterize the rate of OM penetration for -lactams is critical for optimizing antibiotic
monotherapies and combination therapies against MDR Gram-negative organisms.
To characterize permeability, cellular uptake assays have been used to quantify
intracellular drug accumulation over time (17–20). These assays are not feasible for
-lactams in MDR Gram-negative species, since -lactamases rapidly hydrolyze
-lactams in the periplasm. This very feature is, however, exploited by the
Zimmermann-Rosselet penetration assay (7, 21), which assesses the decline of extra-
cellular -lactam concentrations due to -lactamase-mediated hydrolysis in the
periplasm. To date, this assay has been used with single -lactams where the -lactam
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concentrations were quantified spectrophotometrically. This approach limits sensitivity
and specificity and is not feasible for studying multiple -lactams simultaneously.
Assuming rapid hydrolysis in the periplasm, the extracellular concentration of rapidly
penetrating -lactams will decline faster than that of slowly penetrating -lactams. The
rate of OM penetration can then be estimated by comparing the rates of decline in
intact and lysed bacteria. This presents a permeability-limited clearance scenario, which
has been widely applied for studying uptake of metabolically unstable drugs into
hepatocytes in the drug metabolism and pharmacokinetics area (22, 23).
Here, we aimed to develop the first liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS)-based assay, which can quantify the OM permeability of five -lactams
in MDR isolates simultaneously (i.e., a cassette assay). This assay was developed using
carbapenemase (blaKPC-2)-producing clinical isolates of K. pneumoniae and E. cloacae,
which additionally carried other -lactamases. Our K. pneumoniae isolate was poly-
myxin resistant (PBr), whereas the E. cloacae isolate was polymyxin susceptible (PBs); the
latter isolate was identified as belonging to the species E. cloacae. The presence of OM
porins and -lactamases was assessed via whole-genome sequencing and proteomics.
RESULTS
The polymyxin MICs were 64 mg/liter for the K. pneumoniae isolate (KP3800) and
0.5 mg/liter for the E. cloacae isolate (EC3800). The MICs for KP3800 and EC3800 were
128 and 4 mg/liter for imipenem, 256 and 4 mg/liter for meropenem, 128 and
16 mg/liter for cefepime, 64 and 16 mg/liter for ceftazidime, and 256 and 128 mg/liter
for aztreonam, respectively.
Whole-genome sequencing. The KP3800 isolate belonged to K. pneumoniae MLST
type 437 and harbored five -lactamases; these included the blaKPC-2 (carbapenemase),
blaTEM-1B (extended-spectrum -lactamase [ESBL]), blaSHV-182 (ESBL, 99.88% sequence
identity to reference), blaOXA-1 (class D -lactamase), and blaCTX-M-15 (ESBL). The EC3800
belonged to E. cloacae MLST type 270 and carried four -lactamases, including the
blaKPC-2 (carbapenemase), blaACT-7 (AmpC -lactamase, 95.2% sequence identity to
reference), blaCTX-M-8 (ESBL, 99.89% sequence identity to reference), and blaOXA-9 (class
D -lactamase).
Hydrolysis of -lactams in lysed bacteria. We used freshly grown and lysed
bacteria in late exponential growth phase at initial inocula of approximately 6.6  108
CFU/ml (average of replicates) for EC3800 and 1.6  108 CFU/ml for KP3800. The rate of
hydrolysis was measured for five clinically relevant -lactams over periods of up to
120 min. We studied two carbapenems (imipenem and meropenem), two cephalospo-
rins (cefepime and ceftazidime), and aztreonam, all at initial drug concentrations
ranging from 1 to 30 mg/liter. The average unbound plasma concentrations at steady-
state expected at the highest clinical dose in critically ill patients ranged from approx-
imately 8 to 38 mg/liter (see Table S1 in the supplemental material). With EUCAST MIC
breakpoints for our five -lactams ranging from 1 to 4 mg/liter, the studied concen-
trations of 1 to 30 mg/liter covered the clinically relevant range for each drug.
For lysed bacteria using both the discrete and cassette assay, imipenem and
meropenem were hydrolyzed rapidly (Fig. 1 to 4, panels G and H). Cefepime and
aztreonam were also hydrolyzed rapidly, but more slowly than the carbapenems (Fig. 1
to 4, panels I and J). In contrast, ceftazidime hydrolysis was slow in EC3800 and
moderate in KP3800 (Fig. 1 to 4, panel K in all figures). The results from two additional
replicates each for the cassette (Fig. S2 and S3) and discrete (Fig. S4 and S5) assays
showed good reproducibility compared to the results from the first replicate (Fig. 1 to 4).
When -lactams were directly exposed to -lactamases of lysed bacteria, the
estimated intrinsic hydrolysis clearance (CLint; curve fits of individual data sets had an
average r2 of 0.973) was rapid for all -lactams except ceftazidime. Overall, -lactamase
activity was significantly higher for KP3800 compared to EC3800 (P  0.01, paired t test
for the respective drugs). The CLint tended to be smaller for the cassette compared to
that of the discrete assay, likely due to a small extent of drug-drug interaction at the
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-lactamase during the cassette assay; however, the CLint was still rapid for the cassette
assay and the overall decline of -lactam concentrations was permeability limited.
Depletion assay in the supernatant control and viability test. To improve
sensitivity of the intact bacteria assay, we used high inocula of on average 3.3  109
CFU/ml for EC3800 and 7.9  108 CFU/ml for KP3800. This was achieved by concen-
trating bacteria from late-exponential-growth-phase cultures 5-fold via centrifugation
and resuspension. The five -lactams were studied at initial concentrations of 1 to
10 mg/liter in intact bacteria. To demonstrate a lack of remaining -lactamase activity
after the sixth wash in phosphate-buffered saline (PBS), the -lactam concentration was
determined in the supernatant controls (i.e., “prior assay controls”) using an initial
concentration of 3 mg/liter. The -lactam concentrations remained constant over
120 min for all five drugs in the prior assay controls under all conditions (i.e., for both
isolates and for the discrete as well as the cassette assay, Fig. 1 to 4, panels A to E); this
confirmed that extracellular -lactamase activity was minimal after six washes.
To further demonstrate a lack of -lactamase release into PBS during the intact
bacteria assay, additional supernatant controls (i.e., “post assay controls”) were studied;
FIG 1 Concentration-time profiles of imipenem, meropenem, cefepime, ceftazidime, and aztreonam for the cassette assay of the polymyxin-susceptible E.
cloacae isolate EC3800. -Lactams were dosed at 3 mg/liter of each drug for the supernatant control and at 1, 3, or 10 mg/liter of each drug for intact bacteria
arms (A to E). (F) Bacterial density (3.2  109 cells/ml) after six washes and immediately before adding the antibiotics to the intact cell arms. -Lactams were
dosed at 1, 3, 10, or 30 mg/liter of each drug for lysed bacteria arms (G to K). (L) Bacterial density (6.4  108 cells/ml) after the washes and immediately before
lysing. The data (Table 1) represent biological triplicates. The individual profiles for all replicates are presented in the supplemental material.
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these controls used bacteria after six washes which had been further incubated in PBS
for 120 min. After this incubation, bacteria were removed by centrifugation and the
-lactamase activity assessed in the supernatant. All five -lactams were stable in the
“post assay controls” (Fig. S1), confirming a lack of -lactamase release during entire
assay. In addition, we confirmed a lack of bacterial killing of EC3800 and KP3800 under
simultaneous exposure to each of the five -lactams at 10 mg/liter for 2 h in PBS buffer
at a high initial bacterial density. There was no significant decline of viable counts for
both EC3800 and KP3800 after 2 h of exposure to all five -lactams, likely due to the
high initial bacterial density and limited or no growth of bacteria in PBS buffer.
Depletion assay in intact bacteria. In intact EC3800, degradation of imipenem was
extremely rapid and imipenem could only be quantified up to 1 min in the cassette
study (Fig. 1 and 3, panels A). Imipenem was quantifiable up to 5 min in the discrete
assay, since the bacterial density was 5-fold lower than that in the cassette assay.
Imipenem degradation remained relatively fast for intact KP3800 (Fig. 2 and 4, panels
A) but was substantially slower than that for intact EC3800.
FIG 2 Concentration-time profiles of imipenem, meropenem, cefepime, ceftazidime, and aztreonam for the cassette assay of the polymyxin-resistant K.
pneumoniae isolate KP3800. -Lactams were dosed at 3 mg/liter of each drug for the supernatant control and at 1, 3, or 10 mg/liter of each drug for intact
bacteria arms (A to E). (F) Bacterial density (9.0  108 cells/ml) after six washes and immediately before adding the antibiotics to the intact cell arms. -Lactams
were dosed at 1, 3, 10, or 30 mg/liter of each drug for lysed bacteria arms (G to K). (L) Bacterial density (1.8  108 cells/ml) after the washes and immediately
before lysing. The data (Table 1) represent biological triplicates. The individual profiles for all replicates are presented in the supplemental material.
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Meropenem degradation was fast, but 7-fold slower than that of imipenem in
EC3800 (Fig. 1 and 3, panels B); meropenem degradation was slower for intact KP3800
(Fig. 2 and 4, panels B) relative to that of EC3800. Of note, while the downslope of
imipenem and meropenem was roughly comparable for the discrete assay (Fig. 3A and
B, Fig. 4A and B), the bacterial density used for imipenem was considerably smaller than
that used for meropenem studies (Fig. 3F and 4F). Therefore, imipenem penetrated the
OM substantially faster than meropenem.
Compared to imipenem, the rate of depletion was 258-fold slower for cefepime and
at least 2,000-fold slower for aztreonam. For intact EC3800 after 120 min of incubation,
the remaining -lactam concentration was approximately 30% for cefepime and 60%
for aztreonam each compared to their initial concentrations at time zero (Fig. 1 and 3,
C and D). The depletion rates of the non-carbapenem -lactams were even slower for
intact KP3800 (Fig. 2 and 4, panels C and D). Finally, the rate of ceftazidime degradation
was too slow to be robustly characterized (Fig. 1 to 4, panels E). The additional
replicates of the cassette (Fig. S2 and S3) and discrete assay (Fig. S4 and S5) revealed
FIG 3 Concentration-time profiles of imipenem, meropenem, cefepime, ceftazidime, and aztreonam for the discrete assay of the polymyxin-susceptible E.
cloacae isolate EC3800. -Lactams were dosed at 3 mg/liter of each drug for the supernatant control and at 1, 3, or 10 mg/liter of each drug for intact bacteria
arms (A to E). (F) Bacterial density (6.3  108 for imipenem, 4.2  109 for meropenem, 3.6  109 for cefepime, 3.8  109 for aztreonam, and 3.5  109 for
ceftazidime) after six washes and immediately before adding the antibiotic to the intact bacteria arms. -Lactams were dosed at 1, 3, 10, or 30 mg/liter of each
drug for lysed bacteria arms (G to K). (L) Bacterial density (6.3  108 for imipenem, 8.4  108 for meropenem, 7.2  108 for cefepime, 7.6  108 for aztreonam,
and 7.0  108 for ceftazidime) after the washes and immediately before lysing. The data (Table 1) represent biological triplicates. The individual profiles for all
replicates are presented in the supplemental material.
Kim et al. ®













































good reproducibility compared to the first replicate (Fig. 1 to 4). Furthermore, we
utilized the efflux pump inhibitor phenylalanine-arginine -naphthylamide (PAN) at
25 mg/liter and then carried out the cassette assay in intact bacteria. The depletion
rates of all five -lactams with PAN coincubation (Fig. S6 and S7) were compared to
assays without PAN (Fig. 1 to 4 and Fig. S2 to S3).
Determination of OM permeability. After effective removal of extracellular
-lactamase by six washes, the depletion of -lactam concentrations using intact
bacteria can be attributed to periplasmic -lactamase activity. For this scenario, pen-
etration of -lactam molecules through the OM presents the rate-limiting step and the
decline of extracellular -lactam concentrations is permeability limited. To characterize
the time course of -lactam degradation, we developed a mathematical model which
included a distribution clearance (CLd) between the extracellular and periplasmic
space. The CLd was independently estimated based on three biological replicates for
the cassette assay and three biological replicates for the discrete assay. To convert the
estimated CLd to permeability coefficients, the bacterial cell surface area and the initial
FIG 4 Concentration-time profiles of imipenem, meropenem, cefepime, ceftazidime, and aztreonam for the discrete assay of the polymyxin-resistant K.
pneumoniae isolate KP3800. -Lactams were dosed at 3 mg/liter each drug for the supernatant control and at 1, 3, or 10 mg/liter each drug for intact bacteria
arms (A to E). (F) Bacterial density (1.1  108 for imipenem, 3.0  109 for meropenem, 9.5  108 for cefepime, 7.8  108 for aztreonam, and 7.5  108 for
ceftazidime) after six washes and immediately before adding the antibiotic to the intact bacteria arms. -Lactams were dosed at 1, 3, 10, or 30 mg/liter each
drug for lysed cells arms (G to K). (L) Bacterial density (1.1  108 for imipenem, 6.0  108 for meropenem, 1.9  108 for cefepime, 1.5  108 for aztreonam, and
1.6  108 for ceftazidime) after the washes and immediately before lysing. The data (Table 1) represent biological triplicates. The individual profiles for all
replicates are presented in the supplemental material.
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inoculum used in the respective experiment were utilized. Lakaye et al. (24) published
a conversion factor of 132 cm2/1 mg (dry weight) of cells, and one cell contributed
0.28 pg (dry weight) (25). This yields a bacterial surface area of 24.4 cm2/ml for an
average initial inoculum of 6.6  108 CFU/ml for EC3800, equivalent to 3.7 m2 per cell.
Based on this conversion factor and the employed initial inocula, imipenem perme-
ability was 7-fold faster than that of meropenem, 258-fold faster than that of
cefepime, and 2,000-fold faster than that of aztreonam for EC3800 (Table 1). The
permeability coefficient for ceftazidime could not be determined for EC3800 due to
limited -lactamase-mediated hydrolysis of ceftazidime (Fig. 1 and 3, panels E).
When comparing KP3800 to EC3800, the OM permeability coefficients were approx-
imately 5-fold smaller for imipenem, 10-fold smaller for meropenem, and 3-fold smaller
for cefepime in KP3800; however, the permeability coefficient was 6-fold larger for
aztreonam in KP3800. For ceftazidime, the KP3800 isolate displayed more -lactamase-
mediated hydrolysis than EC3800. However, degradation of ceftazidime was too slow to
be reliably determined in intact bacteria. Given this, the permeability coefficient of
ceftazidime was small (likely 3 nm/s) in KP3800. Addition of the efflux pump inhibitor
PAN at 25 mg/liter yielded similar OM permeability coefficients compared to the
cassette assay without efflux pump inhibitor. The OM permeability coefficients were
slightly smaller for the carbapenems and slightly larger for cefepime and aztreonam,
but none of these comparisons with or without PAN was statistically significant (P 
0.05, unpaired t test).
To further assess the robustness of this assay, we ran a single replicate for two
additional K. pneumoniae isolates (KP6478 and KP6484) using the discrete assay.
Although some strain-to-strain variability in the OM permeability was observed (Ta-
ble S2), the results were consistent with those for isolate KP3800, and the ranking of
compounds was the same in all three isolates. The only exception was a faster OM
permeability of ceftazidime in one of the three K. pneumoniae strains.
Proteomics and gene expression. To characterize the OM and efflux pump pro-
files, we used nano-LC/MS/MS to identify three OM porins, one -lactamase and two
efflux pump components. To confirm that the differences in protein expression were
related to changes in mRNA expression, we performed reverse transcription-
quantitative PCR (RT-qPCR) for selected genes (Fig. S8). Proteomics studies assessed the
production of the OM porins OmpA, OmpK36/OmpC, and LamB; the KPC-2 -lactamase;
and the AcrB and TolC efflux pump components. When KP3800 and EC3800 were
compared to K. pneumoniae strain ATCC 13833, OmpK36 was considerably more
abundant in the ATCC strain (Table 2). Moreover, OmpC was more abundant in EC3800
than OmpK36 in KP3800. This correlated with the faster OM permeability in EC3800
compared to that in KP3800. In agreement with a prior publication showing a lack of
OmpK35 in the ATCC strain (26, 27), we did not find this porin in either the ATCC strain
or in our clinical isolates. The KPC-2 carbapenemase was the predominant -lactamase
in our clinical isolates and was produced in even higher abundance in KP3800 than in
TABLE 1 Outer membrane permeability coefficients for imipenem, meropenem, cefepime, aztreonam and ceftazidime for the polymyxin-
susceptible E. cloacae (EC3800) and the polymyxin-resistant K. pneumoniae (KP3800) isolatesa
Assay and colony
Avg OM permeability coefficient (nm/s)  SD
Imipenem Meropenem Cefepime Aztreonam Ceftazidime
Discrete E. cloacae 6,655  2,542 729  155 25.8  15.2 1.34  1.19 NA
Cassette E. cloacae 5,770  1,570 843  292 11.8  4.45 3.20  0.987 NA
Cassette E. cloacae, efflux 3,930  920 402  69.8 12.1  4.26 5.10  0.242 NA
Discrete K. pneumoniae 2,042  338 83.3  9.17 13.6  9.26 8.64  8.46 TSTD
Cassette K. pneumoniae 907  65.7 90.7  6.89 TSTD TSTD TSTD
Cassette K. pneumoniae, efflux 723  124 57.5  21.7 TSTD TSTD TSTD
aData were determined via a discrete and a cassette assay, and additional cassette assay (“efflux”) studies were carried out with 25 mg/liter phenylalanine-arginine
-naphthylamide (PAN) as an efflux pump inhibitor. Estimates represent averages from three biological replicates for the cassette and discrete assays and two
biological replicates for efflux inhibitor assay. TSTD, too slow to be determined (for the initial inocula used; TSTD is equivalent to a permeability coefficient of
0.6 nm/s for the experiments with E. cloacae isolate and 3 nm/s for the K. pneumoniae isolate); NA, not quantifiable in this isolate due to insufficient hydrolysis of
ceftazidime.
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EC3800 (Table 2). This agreed with the substantially faster hydrolysis rate in lysed
KP3800 compared to that of lysed EC3800.
DISCUSSION
This study developed a new, efficient OM permeability assay that can simultane-
ously quantify the permeability coefficients of five clinically relevant -lactams. This
assay has been optimized to assess OM permeability in MDR clinical isolates of K.
pneumoniae and E. cloacae and should be applicable to a range of other isolates with
different -lactamases. Adapting this assay to a larger range of strains for the two
tested pathogens should be reasonably readily achievable based on the detailed
methods described here; implementing this assay in cassette mode will greatly benefit
from support by a bioanalytical LC-MS/MS team. Expanding this assay to other patho-
gens may require further, pathogen-specific optimization.
In our isolates, there was no drug-drug interaction during influx for drug concen-
trations of up to 10 mg/liter for all five -lactams simultaneously, as shown by the
similar OM permeability coefficients obtained via the discrete and cassette assay.
Consistent between the cassette and discrete assay, imipenem penetrated the OM of
EC3800 approximately 7-fold faster than meropenem, 258-fold faster than cefepime,
and 2,000-fold faster than aztreonam. Ceftazidime hydrolysis was very limited in
EC3800 and moderate in KP3800, as expected based on prior reports on KPC-2 (28, 29);
therefore, OM permeability estimates for ceftazidime carried more uncertainty, espe-
cially for EC3800.
The faster penetration of imipenem compared to meropenem in EC3800 was much
more pronounced than the previously reported 2.74-fold faster OM permeability for
imipenem over meropenem in P. aeruginosa (8). The permeability coefficient for
cefepime in EC3800 was in the range of permeability coefficients (9.2 to 29 nm/s)
reported previously for E. cloacae complex (9, 30, 31). Likewise, one prior study (30)
reported permeability coefficients of 1 nm/s for ceftazidime and another study found
an extremely low permeability coefficient of 0.032 nm/s for aztreonam (24).
The permeability coefficients were approximately 5- to 10-fold slower for KP3800
compared to those for EC3800, depending on the -lactam. We are not aware of
published permeability data for carbapenems in E. cloacae complex or K. pneumoniae
(32). To the best of our knowledge, this is the first report showing a substantially faster
OM penetration of carbapenems (especially imipenem) compared to the studied
noncarbapenem -lactams in K. pneumoniae and E. cloacae. Although considerably
more work is required to prove the following hypothesis, the substantially faster OM
permeability of imipenem compared to that of meropenem might be explained as
follows. Imipenem has a leaner side chain than meropenem. Meropenem carries the
positive charge on the nitrogen of a five-ring heterocycle (pKa2  8.3); in contrast,
imipenem is a stronger base (pKa2  10.6) and the charge is located on a more flexible
linear side chain at the R3 position. Moreover, imipenem lacks the methyl-group which
is present in meropenem at the R2 position of the carbapenem backbone structure.
These features might allow imipenem to align its negative and more defined positive
TABLE 2 Protein production in strain ATCC 13833, a polymyxin-resistant K. pneumoniae
isolate (KP3800), and a polymyxin-susceptible E. cloacae isolate (EC3800)
Protein







OmpA 170 237 90.0
OmpK35/OmpF 0.00 0.00 0.00
OmpK36/OmpC 36.0 9.00 18.0
LamB 81.0 46.0 24.0
KPC-2 0.00 12.0 3.00
AcrB 9.00 9.00 9.00
TolC 9.00 9.00 9.00
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charges more efficiently while passing through OM porin channels. Future structural
biology and computational chemistry work is warranted.
The vast majority of earlier studies used spectrophotometric methods with UV
absorption to quantify -lactam concentrations (7). The proposed new cassette assay
offers several advantages. The LC-MS/MS assay we used has greatly improved selec-
tivity and sensitivity compared to spectrophotometric methods. This allowed us to
employ the LC-MS/MS assay in cassette and discrete modes and to demonstrate a lack
of influx-related drug-drug interactions for the five -lactams. Therefore, this assay
enables characterization of the rate of OM permeability of double -lactam combina-
tions (12). The ranking of OM permeability coefficients matched between the discrete
and cassette assay, and the results were comparable (Table 1). The cassette assay
allowed us to better standardize the initial inoculum when comparing different
-lactams, since the same batch of bacteria is used to hydrolyze each -lactam. In
addition, the cassette assay provides improved efficiency for future studies in a larger
number of strains (Table S2). The discrete assay offers the advantage that it completely
avoids potential drug-drug interactions at any stage and that the bacterial density can
be fine-tuned according to the rate of OM permeability (i.e., low bacterial density for
rapidly penetrating drugs and vice versa). This improves the dynamic range of the
assay. Importantly, both versions of this assay directly characterize OM permeability in
MDR clinical isolates of K. pneumoniae and E. cloacae and do not rely on model systems.
Employing both the discrete and the cassette versions of this assay allowed us to show
a lack of impact of drug-drug interactions relating to influx, efflux, and -lactamase
activity. Therefore, combining both assay variants offers additional insights.
Our OM permeability data show a much faster penetration for EC3800 compared to
that of KP3800. Proteomics confirmed this finding by revealing a lower production of
the OmpK36 porin in KP3800 compared to the production of OmpC in EC3800 (Table 2).
Likewise, production of the KPC-2 -lactamase was 3-fold higher in KP3800, which
correlated with the observed rate of hydrolysis in lysed bacteria (Fig. 1 to 4). The greatly
decreased OM permeability and the increased KPC-2 -lactamase production in KP3800
compared to those in EC3800 make the former isolate extensively more difficult to kill
by -lactam antibiotics, in agreement with the observed MICs. This demonstrates that
the combination of our new OM permeability assay, whole-genome sequencing, and
proteomics can provide mechanistic insights, which will be important for the future
design of efficacious combination dosing strategies.
Two major OM porins, OmpK35 and OmpK36, have been identified in K. pneumoniae
and shown to be relevant for -lactam penetration. Lack of production of either or both
of these porins has been shown to increase the MIC to certain -lactams (33). When the
large-diameter porins OmpK35 and OmpK36 are not produced, some data suggest that
a normally quiescent porin, OmpK37, may contribute to the OM penetration of car-
bapenems (33). For E. cloacae, outer membrane porins OmpF and OmpC have been
identified and are involved in OM penetration (4). This may have contributed to the
faster OM permeability for -lactams in EC3800 (Table 2). Of note, we did not find
differences in the production of the AcrB and TolC efflux pump components between
either of our isolates or the ATCC strain. The presence or absence of the efflux pump
inhibitor PAN did not significantly affect the OM permeability estimates of our
-lactams in EC3800 and KP3800. This suggested that efflux did not affect the OM
permeability results in the tested strains.
These mechanistic insights provide a foundation to inform efficacious antibiotic
(combination) dosing strategies, which hold promise to combat MDR K. pneumoniae
and E. cloacae. Double -lactam combination therapy has shown promising efficacy in
early clinical trials for patients with infections by susceptible Klebsiella spp. (12, 34, 35);
this topic has received increasing attention. When each -lactam inactivates its highest
affinity PBP target, double -lactam combination therapy offers the potential to
inactivate an optimal set of PBPs. The present work revealed dramatic differences in the
rate of OM penetration, which likely affect the time course of PBP inactivation. More-
over, the new cassette assay allowed us to demonstrate the absence of a drug-drug
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interaction during influx when five -lactams were used simultaneously at clinically
relevant concentrations (Table 1 and Table S1). This supports the use of double
-lactam combinations in K. pneumoniae and suggests further in vitro studies for E.
cloacae. Future studies are also warranted to assess potential influx-related interactions
between -lactams and -lactamase inhibitors.
In conclusion, we developed and validated here a novel LC-MS/MS-based assay that
can quantify the OM permeability of five -lactams simultaneously for MDR K. pneu-
moniae and E. cloacae. Imipenem penetrated the OM at least 197-fold faster than the
tested noncarbapenem -lactams in our E. cloacae isolate and at least 118-fold faster in
our K. pneumoniae isolate. Of note, imipenem penetrated substantially faster than
meropenem. These findings were consistent between both isolates and between the
cassette and discrete assay. The OM permeability was substantially slower and the
-lactamase production considerably greater in our K. pneumoniae isolate. Combined
with supportive whole-genome sequencing and proteomics data, this new assay
efficiently ranked the OM permeabilities of different clinically relevant -lactams in our
MDR clinical isolates. Overall, these new insights hold excellent promise to significantly
enhance our mechanistic understanding of target site penetration, the rate of receptor
binding and subsequent bacterial killing for combating MDR Gram-negative strains.
MATERIALS AND METHODS
Bacterial strains and reagents. One carbapenem-resistant clinical isolate each of K. pneumoniae
(KP3800) and E. cloacae (EC3800) were used for all OM permeability studies. Two additional K. pneu-
moniae isolates (KP6478 and KP6484) were used for additional OM permeability studies to further
support the developed assay and obtain insights on strain-to-strain variability. Imipenem and mero-
penem were purchased from AK Scientific (Union City, CA). Ceftazidime, cefepime, aztreonam, and PAN
were obtained from Chem-Impex International (Wood Dale, IL). Water and methanol (both LC/MS grade)
were purchased from Fisher Scientific (Fair Lawn, NJ). Formic acid was acquired from Sigma-Aldrich (St.
Louis, MO). Bacteria were grown in cation-adjusted Mueller-Hinton broth (MHII; BD BBL, Sparks, MD), and
agar MICs (14) were determined according to CLSI guidelines (14, 36).
To predict the clinically relevant range of -lactam concentrations, we performed Monte Carlo
simulations to calculate the average unbound concentration at steady state in critically ill patients at the
highest clinical dose (5). These simulations were performed for a continuous infusion and based on a
literature review for the pharmacokinetics of each compound (imipenem [37–40], meropenem [41–45],
cefepime [46], ceftazidime [47, 48], and aztreonam [38, 49]).
Supernatant control, intact, and lysed cell preparation. Bacteria (i.e., one colony) were grown in
50 ml of MHII broth for 4 h at 37°C. During this time, isolate EC3800 reached a density of approximately
6.0  108 CFU/ml and KP3800 of approximately 1.5  108 CFU/ml. These bacteria were in mid- (to late-)
exponential growth phase. Bacteria were centrifuged at 4,750  g for 5 min, the supernatant was
carefully discarded, and the bacterial pellet was resuspended in 50 ml of 50 mM potassium phosphate
buffer at pH 7.0 containing 5 mM MgCl2 following prior studies (50). This washing process was repeated
six times. After the last wash, viable counts of the resuspended bacteria were determined. One part of
the bacterial suspension was lysed by ultrasonication, and the other part was concentrated 5-fold to form
the intact bacteria group. Due to rapid penetration of imipenem, this bacterial concentration step was
not performed for the discrete assay of imipenem.
To evaluate the remaining -lactamase activity after the washing steps, the supernatant of the
washed and 5-fold concentrated bacterial suspension was carefully obtained at 0 h (“prior assay
controls”). To additionally assess the extent of potential release of -lactamase enzymes into the
medium, the washed and 5-fold-concentrated bacterial suspension was further incubated for 2 h in PBS
(“post assay controls”). For both the prior and post assay controls, the supernatant was obtained via
centrifugation and used to quantify extracellular -lactamase activity.
OM permeability assay. For the cassette assay, imipenem, meropenem, ceftazidime, cefepime, and
aztreonam were added simultaneously, each at a concentration of 1, 3, or 10 mg/liter to the three intact
bacteria arms (i.e., each arm used the same concentration of the five antibiotics). For the four lysed
bacteria arms, 1, 3, 10, or 30 mg/liter of each -lactam were used; the prior and post assay supernatant
controls were spiked with 3 mg/liter of each -lactam. The same range of drug concentrations was used
for the discrete drug assay. Serial samples for LC-MS/MS analysis of antibiotic concentrations in PBS over
time were collected up to 120 min post-dosing.
To investigate a potential contribution of efflux on the estimated OM permeability coefficients,
additional cassette assay studies were performed using intact and lysed bacteria coincubated with the
efflux pump inhibitor PAN at 25 mg/liter; this concentration was chosen based on a prior study (51). The
OM permeability coefficients in presence and absence of PAN was compared for each -lactam.
To further assess the robustness of the assay, OM permeability studies were performed in two
additional K. pneumoniae isolates (KP6478 and KP6484) via the discrete assay. These results also provided
first insights on strain-to-strain variability.
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LC-MS/MS analysis. Imipenem, meropenem, ceftazidime, cefepime, and aztreonam were quantified
by using LC-MS/MS. Our system consisted of a 1260 HPLC (Agilent) and a 6460 triple quadrupole mass
spectrometer (Agilent). Separation was achieved using a Kinetex 2.6 m Polar C18 LC column
(50  2.1 mm) with a run time of 7.0 min. Mobile phases consisted of 0.1% formic acid in water (phase
A) and methanol (phase B) at a flow rate of 0.4 ml/min in gradient mode. The mass transition (MRM) of
imipenem m/z 300.1 ¡ 142.1, cefepime m/z 481.1 ¡ 396.0, meropenem m/z 384.2 ¡ 141.1, ceftazidime
m/z 547.1 ¡ 468.0, aztreonam 436.1 ¡ 313.1, and the internal standard (diphenpydramine) m/z
256.2 ¡ 167.2 were monitored in positive-ion mode.
Whole-genome sequencing. Genomic DNA was isolated using a DNeasy Blood and Tissue kit
according to the “purification of total DNA from animal tissues” and “pretreatment for gram-negative
bacteria pretreatment” protocols. Genomic DNA was quantified using the Quant-iT RiboGreen assay (Life
Technologies.) Libraries were prepared from 1 ng of gDNA using a Nextera XT DNA Library Prep kit, and
paired-end 250 cycle sequencing was performed on a MiSeq sequencer (Illumina). Genomes were
assembled with the CLC Genomic Workbench and assemblies submitted to CGE MLST, ResFinder (52),
and the CARD (53) servers for strain typing and resistance genotyping.
Analysis of gene expression. The relative mRNA levels of selected genes (OmpK35/OmpF, OmpK36/
OmpC, acrB, blaKPC-2 and mgrB) were determined by real-time RT-qPCR according to previously described
protocols (54, 55). Total RNA was obtained with the RNeasy minikit (Qiagen). Fifty nanograms of purified
RNA was used for one-step reverse transcription and real-time quantitative PCR run in ViiA 7 real-time
PCR system usinga Power SYBR green RNA-to-CT 1-Step kit (Thermo Fisher). The 16S rRNA housekeeping
gene rrsE was used to normalize the expression levels, and the results were referred to K. pneumoniae
ATCC 13833 or EC3800. All RT-PCRs were performed in duplicate, and the mean values of expression from
six independent experiments were considered. The primers used are listed in Fig. S8 in the supplemental
material.
Proteomics and MS analysis. Nano-liquid chromatography-tandem mass spectrometry (Nano-LC-
MS/MS) was performed on a Thermo Scientific Q Exactive HF Orbitrap mass spectrometer. The instrument
was equipped with an EASY spray nanospray source (Thermo Fisher Scientific, San Jose, CA) and operated
in positive-ion mode. An EASY Spray PepMAP column (Thermo Fisher) was used for chromatographic
separations (C18, 75 m [inner diameter], 25-cm length, 3 m, 100-Å pore size).
The scan sequence of the mass spectrometer was based on the TopFive method; analyses were
programmed for a full scan recorded from 350 to 2,000 Da, and an MS/MS scan was used to generate
product ion spectra. This approach determines the amino acid sequence in consecutive instrument scans
for the ten most abundant peaks.
For database searching, all MS/MS samples were analyzed using the Sequest (XCorr Only; Thermo
Fisher Scientific, San Jose, CA; version IseNode in Proteome Discoverer 2.2.0.388). Charge state decon-
volution and deisotoping were not performed. Sequest (XCorr Only) was set up to search the Swiss-Prot
database (version 2017_06; containing 554,860 sequences and 198,649,153 residues) using trypsin as
digestion enzyme. Sequest (XCorr Only) was searched with a fragment ion mass tolerance of 0.020 Da
and a parent ion tolerance of 10.0 ppm. Carbamidomethyl of cysteine was specified in Sequest (XCorr
Only) as a fixed modification. Deamidation of asparagine and oxidation of methionine were specified in
Sequest (XCorr Only) as variable modifications.
As criteria for protein identification, the Scaffold package (Scaffold_4.8.7; Proteome Software Inc.,
Portland, OR) was used to validate MS/MS-based peptide and protein identifications. Peptide identifi-
cations were accepted if they could be established at 95.0% probability by the Peptide Prophet
algorithm (56) with the Scaffold delta-mass correction. Protein identifications were accepted if they could
be established at 99.0% probability and contained at least one identified peptide. Protein probabilities
were assigned by the Protein Prophet algorithm (57). Proteins which contained similar peptides and
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of
parsimony; likewise, proteins sharing significant peptide evidence were grouped into clusters.
Estimation of permeability coefficients. We developed a time course model to describe the drug
concentrations in the extracellular and periplasmic space. This model included processes for -lactam
penetration from the extracellular into the periplasmic space, as well as -lactamase-mediated hydrolysis
of -lactams in the periplasm of intact bacteria or in the extracellular space of lysed bacteria. As shown
by the control arms, thermal degradation of the -lactams was minimal over the 120-min study period.
The supernatant control group was utilized to demonstrate the lack of any remaining extracellular
-lactamase activity after washing; the associated degradation clearance (CLdeg) was initially estimated
and eventually fixed to zero. The differential equation for the amount of -lactam (S) in the extracellular
space of the control group was as follows:
d S
dt
 CLdeg · S/VS
The initial condition was set to 3 g for S, and the supernatant volume (VS) was fixed at 1 ml.
For intact bacteria, the distribution of -lactams from the extracellular into periplasmic space was
described by the distribution clearance (CLd). The potential degradation of extracellular -lactam was
described by CLdeg. In the periplasm, the -lactamase mediated hydrolysis, followed Michaelis-Menten
kinetics with a maximum rate of degradation (Vmax) and a -lactam concentration (Km; Michaelis-Menten
constant) associated with half-maximal Vmax. The differential equations for the amounts of -lactam in
extracellular (E) and periplasmic (P) space were (CE and CP represent the -lactam concentrations in the
extracellular and periplasmic space):
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 –CF · CLd · CE – CLdeg · CE  CF · CLd · CP
d P
dt
 CF · CLd · CE – CF · Vmax · CP) ⁄ (Km  CP) – CF · CLd · CP
The concentration factor (CF) was introduced to account for the 5-fold concentrated bacterial
density of the intact bacteria group compared to that of the lysed group. The CF was 5 for all intact
bacteria studies, except for the discrete studies with imipenem where CF was set to 1 (to reflect the
experimental condition). The initial condition was set to 1, 3, or 10 g for E and to 0 g for P.
Theoretically, the volume of 109 bacterial cells is only 0.001 ml (and the periplasmic volume is a fraction
of this). We confirmed during model building, that the chosen ratio of the periplasmic to the extracellular
volume did not affect the CLd estimates, as long as the periplasmic volume was much smaller than the
extracellular volume. We tested ratios of 5%, 1%, and 0.5% in our robust differential equation solver and
confirmed this result via Laplace transformation (not shown). To enhance the stability of the differential
equation solver (58), we fixed the periplasmic volume (VP) to a value of 0.05 ml (which is considerably
larger than the true biological volume [59]) and the extracellular volume (VE) to 0.95 ml. This choice had
minimal impact on the CLd estimates (CLd  distribution_rate_constant · VE).
In lysed bacteria, -lactams were freely exposed to -lactamase enzymes. The hydrolysis followed the
same Michaelis-Menten kinetics as in the aforementioned periplasmic compartment. A dilution factor of
20 was applied for Vmax, to reflect the dilution of periplasmic content in the entire 1-ml volume after lysis
(i.e., 0.05 ml versus 1 ml). The differential equation for the amount of drug in lysed bacteria arms (L) was





(Vmax ⁄ 20 · CL)
(Km  CL)
The initial conditions were set to 1, 3, 10, or 30 g for L at time zero, and the lysed bacteria volume
(VL) was fixed to 1 ml.
To convert the estimated distribution clearance (CLd; unit, ml/min) to a permeability coefficient
(nm/s), the bacterial surface area is needed. Lakaye et al. (24) published a conversion factor of 132 cm2
per 1 mg (dry weight) of cells, and one cell contributed 0.28 pg (dry weight) (25). Therefore, one bacterial
cell contributed a surface area of 3.7 m2. This estimate matched well with a previously published value
(60). Consequently, for EC3800 6  108 cells were equivalent to a surface area of 22.2 cm2, and for KP3800





Estimation. To estimate the model parameters, we used the first-order conditional estimation
method with the interaction option (FOCEI) in the NONMEM software (version 7.4; ICON, Dublin,
Ireland) (61). The Pirana facilitator tool was employed (62).
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